Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/16/2021 09/17/2021 09/20/2021 09/21/2021 09/22/2021 Date
165.22(c) 164.75(c) 163.81(c) 164.53(c) 164.53 Last
5 665 537 13 422 106 7 271 017 6 663 566 1 214 131 Volume
-0.12% -0.28% -0.57% +0.44% 0.00% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 94 407 M - -
Net income 2021 22 809 M - -
Net Debt 2021 1 880 M - -
P/E ratio 2021 19,1x
Yield 2021 2,53%
Sales 2022 97 448 M - -
Net income 2022 23 971 M - -
Net cash position 2022 3 430 M - -
P/E ratio 2022 17,6x
Yield 2022 2,70%
Capitalization 433 B 433 B -
EV / Sales 2021 4,61x
EV / Sales 2022 4,41x
Nbr of Employees 134 500
Free-Float 84,3%
More Financials
Company
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care,... 
Sector
Pharmaceuticals
Calendar
09/28 | 10:00amPresentation
More about the company
Ratings of Johnson & Johnson
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about JOHNSON & JOHNSON
08:58aPRO BANKRUPTCY BRIEFING : J&J Beats Injury Lawyers on Talc Bankruptcy; Judge Questions Tal..
DJ
09/21JOHNSON & JOHNSON : Unit Collaborates With Persephone Biosciences On Stool Analysis
MT
09/21Shangula Rages Against West's Vaccine Nationalism
AQ
09/21Johnson & Johnson Data Shows COVID-19 Booster Shots 94% Effective Against Moderate to S..
MT
09/21Today on Wall Street: Markets at a pivot point
09/21JOHNSON & JOHNSON : Says New Data Show Booster Shot Increases COVID-19 Protection
MT
09/21J&J : Booster dose of its COVID shot prompts strong response
AQ
09/21JOHNSON & JOHNSON : Says New Data Shows a Booster of its One-Shot Vaccine Increases COVID-..
MT
09/21JOHNSON & JOHNSON : Announces Real-World Evidence and Phase 3 Data Confirming Strong and L..
PR
09/21Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and ..
CI
09/21JOHNSON & JOHNSON : COVID-19 Vaccine to Reportedly Arrive in India Next Month
MT
09/20JOHNSON & JOHNSON : The Janssen Pharmaceutical - RYBREVANT (amivantamab-vmjw) Provides Hig..
AQ
09/20JOHNSON & JOHNSON : Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with ..
AQ
09/20JOHNSON & JOHNSON : - New Data on RYBREVANT (amivantamab-vmjw) in Combination with Lazerti..
AQ
09/20JOHNSON & JOHNSON : Unit Reports Additional Data from Early Stage Trial of Lung Cancer Reg..
MT
More news
News in other languages on JOHNSON & JOHNSON
09/21STUDIE : Einmal-Impfstoff von Johnson & Johnson wirksamer durch Zweitimpfung
09/21Une unité de Johnson & Johnson collabore avec Persephone Biosciences pour l'analyse des..
09/21Johnson & Johnson annonce des données en faveur d'une dose de rappel
09/21Prudent rebond à Wall Street après les craintes sur Evergrande
09/21Les données de Johnson & Johnson montrent que les injections de rappel de COVID-19 sont..
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 164,53 $
Average target price 185,83 $
Spread / Average Target 12,9%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.54%433 122
ROCHE HOLDING AG9.82%321 584
PFIZER, INC.20.08%246 246
NOVO NORDISK A/S52.07%234 070
ELI LILLY AND COMPANY36.32%208 668
ABBVIE INC.0.00%189 353